LYMON
Financiado
Laser-assisted sYnthesis of Magnetically mOtile plasmonic chiral Nanocatalysts
Catalysis holds immense significance in chemical manufacturing, being a key player in developing sustainable industrial processes with limited energy & resource consumption. In pharmaceutical industry, catalysis is crucial for ena...
Catalysis holds immense significance in chemical manufacturing, being a key player in developing sustainable industrial processes with limited energy & resource consumption. In pharmaceutical industry, catalysis is crucial for enabling mass production of affordable life-saving drugs. However, developing efficient catalysts for this sector poses a formidable challenge due to the inherent asymmetry of many biological processes. This is particularly critical in producing anticancer drugs because their synthesis relies on intermediates or reactions whose asymmetric nature, known as chirality, withholds their massive production, limiting equal global access to best health treatments.
An up-and-coming solution to address this dilemma is resorting to chiral plasmonic nanoparticles (NPs), as their outstanding optical rotation activity makes them well-suited for applications like polarization-sensitive photocatalysis, especially in the context of anticancer drug development. However, unleashing its full potential hinges on imbuing these chiral NPs with unusual properties like magnetism, allowing safe removal from products & recyclability without generating chemical waste. To date, creating a plasmonic structure that seamlessly integrates chirality with magnetic motility remains largely underexplored.
The LYMON project addresses this conundrum by expanding the repertoire of chiral nanocatalyst construction methods through a groundbreaking laser-based pathway. This innovative approach, supported both experimentally & theoretically, promises to bring a new generation of highly specific magnetic chiroplasmonic nanocatalysts characterized by their ability to be reused multiple times. All of this permiting reducing wasteful side reactions & improving control over pharmaceutical production, especially for anticancer drugs. Moreover, it promises to expand the horizons of synthetic chemistry, paving the way for cutting-edge routes to produce highly efficient & selective molecules.
ver más
Duración del proyecto: 34 meses
Fecha Inicio: 2024-05-03
Fecha Fin: 2027-03-31
Fecha Fin: 2027-03-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-03
HORIZON EUROPE
No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Líder del proyecto
UNIVERSITA DEGLI STUDI DI PADOVA
No se ha especificado una descripción o un objeto social para esta compañía.
N.D. |
Participante